SG Americas Securities’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

SG Americas Securities’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,609	Closed	-$452K	–	3244
2018 Q3	$452K	Buy	+7,609	New	+$444K	﹤0.01%	2158
2017 Q2	–	Sell	-5,175	Closed	-$219K	–	3416
2017 Q1	$219K	Sell	5,175 -14,134	-73%	-$593K	﹤0.01%	2371
2016 Q4	$749K	Sell	19,309 -6,289	-25%	-$254K	0.01%	1471
2016 Q3	$1.07M	Buy	25,598 +19,870	+347%	+$816K	0.01%	1115
2016 Q2	$212K	Buy	+5,728	New	+$225K	﹤0.01%	2088
2014 Q3	–	Sell	-2,723	Closed	-$119K	–	2785
2014 Q2	$119K	Buy	+2,723	New	+$110K	﹤0.01%	2276

Other funds holding PBE

ACM

Arlington Capital Management Arlington Heights, Illinois $177M AUM 44.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SG Americas Securities's PBE Position: Q4 2018 in Review

SG Americas Securities sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2018, closing a stake of 7,609 shares — an estimated $452K sold.

SG Americas Securities first reported a position in PBE in Q2 2014 and held it in 6 quarters. The position peaked at $1.07M in Q3 2016. 71 funds tracked by Wall St. Rank hold PBE as of Q4 2018.

SG Americas Securities reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2018 after selling out during the quarter.
SG Americas Securities sold 7,609 Invesco Biotechnology & Genome ETF shares in Q4 2018, an estimated $452K.
SG Americas Securities first reported a position in Invesco Biotechnology & Genome ETF in Q2 2014 and held it in 6 quarters.
SG Americas Securities's Invesco Biotechnology & Genome ETF position peaked at $1.07M in Q3 2016.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2018.

Based on SG Americas Securities's 13F filing for Q4 2018, filed 1 Feb 2019.